Surf Bio, a biopharmaceutical company transforming the delivery of antibodies and biologics, announced today that a peer-reviewed study conducted by researchers at Stanford University and published in ...

Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says ...

In these videos, Douglas H. Jones, MD, the medical director and CEO of Global Allergy Immune Network, discusses the latest developments in the treatment and of hereditary angioedema.

The intervention being tested is Efruxifermin, administered via subcutaneous injection. It is designed to improve liver health in patients with NASH/MASH by reducing liver fat and fibrosis. This ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

The interventions being tested include risankizumab, ABBV-382, and lutikizumab. These drugs are administered either as subcutaneous injections or intravenous infusions, with the goal of reducing ...

Daewoong Pharmaceutical Co. Ltd. and Daewoong Therapeutics Inc. reported that their self-developed microneedle patch loaded with semaglutide demonstrated 80% relative bioavailability compared to an ...

The FDA's approval of Alhemo (concizumab-mtci) revolutionizes hemophilia treatment, offering a simpler, subcutaneous injection for better bleed control and patient independence.

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist, previously approved as IMCIVREE ® by the FDA, the EMA, and UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) for obesity due to ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.